Skip to main content

Table 2 The laboratory characteristics at baseline

From: Effects of statin therapy on chronic kidney disease patients with coronary artery disease

Variables CKD + CAD CKD P a
(n = 128) (n = 126)
Triglycerides (mmol/l) 1.7 ± 1.1 2.5 ± 1.3 < 0.001
Total cholesterol (mmol/l) 4.8 ± 1.3 6.6 ± 2.8 < 0.001
LDL-C (mmol/l) 6.7 ± 1.9 4.1 ± 2.4 < 0.001
HDL-C (mmol/l) 1.0 ± 0.4 1.3 ± 0.4 < 0.001
Glucose (mmol/l) 7.3 ± 4.4 9.1 ± 5.2 0.003
HbA1c (%) 6.5 ± 1.2 7.9 ± 2.3 < 0.001
SBP (mmHg) 137.1 ± 31.2 139.3 ± 21.9 0.517
DBP (mmHg) 78.3 ± 15.1 73.1 ± 10.2 0.001
ApoA-I (g/l) 1.3 ± 2.8 1.3 ± 0.3 0.999
ApoB (g/l) 1.0 ± 2.2 1.0 ± 0.3 0.999
ApoA-I/B 1.3 ± 0.3 1.4 ± 0.5 0.054
Lp (a) (ng/ml) 382.3 ± 326.4 373.4 ± 394.2 0.845
  1. Data are presented as mean ± SD
  2. CAD coronary artery disease, CKD chronic kidney disease, HbA1c hemoglobin A1c, ApoA-I apolipoprotein A-I, ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, SBP systolic blood pressure, DBP diastolic blood pressure, Lp (a) lipoprotein (a)
  3. a indicates the comparison of mean between CKD + CAD group and CKD group